PE20161218A1 - (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 - Google Patents
(2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1Info
- Publication number
- PE20161218A1 PE20161218A1 PE2016001236A PE2016001236A PE20161218A1 PE 20161218 A1 PE20161218 A1 PE 20161218A1 PE 2016001236 A PE2016001236 A PE 2016001236A PE 2016001236 A PE2016001236 A PE 2016001236A PE 20161218 A1 PE20161218 A1 PE 20161218A1
- Authority
- PE
- Peru
- Prior art keywords
- oxazepan
- carboxamides
- phenylethyl
- cyano
- cyane
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Epoxy Compounds (AREA)
Abstract
Se refiere a un compuesto derivado de (2S)-N-[(1S)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas de formula I o sales farmaceuticamente aceptables, donde: R1 es (a); R2 es hidrogeno, F, Cl, Br, entre otros; R3 es hidrogeno, F, Cl, CN, entre otros; o R1 es (b), (c), entre otros, donde: X es O, S o CF2; Y es O o S; R6 es alquilo C1-C3 opcionalmente sustituido por 1, 2 o 3 F, OH, entre otros; R7 es F, Cl o CH3. Son compuestos preferidos: (2S)-N-[(1S)-1-Ciano-2-(4'-cianobifenil-4-il)etil]-1,4-oxazepan-2-carboxamida; (2S)-N-{(1S)-1-Ciano-2-[4-(3-metil-2-oxo-2,3-dihidro-1,3-benzoxazol-5-il)fenil]etil}-1,4-oxazepan-2-carboxamida; entre otros. Tambien se refiere a un metodo de tratamiento y a una composicion farmaceutica. Dichos compuestos inhiben la actividad de la dipeptidilpeptidasa (DPP1), siendo utiles en el tratamiento de enfermedades respiratorias tales como asma, enfermedad pulmonar obstructiva cronica (COPD), entre otros
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461931090P | 2014-01-24 | 2014-01-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20161218A1 true PE20161218A1 (es) | 2016-11-27 |
Family
ID=52432834
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2016001236A PE20161218A1 (es) | 2014-01-24 | 2015-01-23 | (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 |
Country Status (37)
Country | Link |
---|---|
US (16) | US9522894B2 (es) |
EP (3) | EP3744714A1 (es) |
JP (5) | JP6469711B2 (es) |
KR (1) | KR102417684B1 (es) |
CN (2) | CN110483492B (es) |
AP (1) | AP2016009322A0 (es) |
AR (1) | AR099177A1 (es) |
AU (4) | AU2015208932C1 (es) |
BR (1) | BR112016016224B1 (es) |
CA (1) | CA2935625C (es) |
CL (1) | CL2016001889A1 (es) |
CR (1) | CR20160327A (es) |
CY (2) | CY1120049T1 (es) |
DK (2) | DK3097086T3 (es) |
DO (1) | DOP2016000175A (es) |
EA (1) | EA032794B1 (es) |
ES (2) | ES2658516T3 (es) |
HK (2) | HK1225730B (es) |
HR (2) | HRP20180116T1 (es) |
HU (2) | HUE052421T2 (es) |
IL (3) | IL246614B (es) |
LT (2) | LT3097086T (es) |
MX (1) | MX368840B (es) |
MY (1) | MY194850A (es) |
NO (1) | NO2699580T3 (es) |
NZ (2) | NZ722063A (es) |
PE (1) | PE20161218A1 (es) |
PH (1) | PH12016501439B1 (es) |
PL (2) | PL3323814T3 (es) |
PT (2) | PT3323814T (es) |
RS (2) | RS56919B1 (es) |
SG (2) | SG11201606052TA (es) |
SI (2) | SI3323814T1 (es) |
TW (1) | TWI690517B (es) |
UY (1) | UY35963A (es) |
WO (1) | WO2015110826A1 (es) |
ZA (2) | ZA201605856B (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO2699580T3 (es) | 2014-01-24 | 2018-02-24 | ||
US20180028541A1 (en) * | 2016-07-29 | 2018-02-01 | Astrazeneca Ab | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors for treating bronchiectasis |
US20190247400A1 (en) * | 2018-02-07 | 2019-08-15 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating granulomatosis with polyangiitis |
EP3758708A1 (en) | 2018-03-01 | 2021-01-06 | AstraZeneca AB | Pharmaceutical compositions comprising (2s)--{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide |
US20210322438A1 (en) * | 2018-07-17 | 2021-10-21 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis |
JP2021530513A (ja) * | 2018-07-17 | 2021-11-11 | インスメッド インコーポレイテッド | 炎症性腸疾患を処置するための特定の(2s)−n−[(1s)−1−シアノ−2−フェニルエチル]−1,4−オキサゼパン−2−カルボキサミド |
CN111689923B (zh) * | 2019-03-12 | 2022-11-08 | 中国科学院上海药物研究所 | 一个具有逆转肿瘤多药耐药活性的环脂肽化合物、其制备方法及用途 |
JP2022553549A (ja) * | 2019-10-23 | 2022-12-23 | チョン クン ダン ファーマシューティカル コーポレーション | 慢性閉塞性肺疾患(copd)の予防または治療用の組成物 |
EP4182700A1 (en) * | 2020-07-20 | 2023-05-24 | Insmed Incorporated | Methods for extracting neutrophil serine proteases and treating dipeptidyl peptidase 1-mediated conditions |
CN115996923A (zh) | 2020-08-26 | 2023-04-21 | 四川海思科制药有限公司 | 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途 |
US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
CN114159446A (zh) * | 2020-09-11 | 2022-03-11 | 中国科学院上海营养与健康研究所 | 组织蛋白酶c抑制剂在治疗肿瘤转移中的应用 |
MX2023006194A (es) | 2020-12-04 | 2023-06-09 | Reistone Biopharma Company Ltd | Inhibidor de molecula peque?a de catepsina c y uso medicinal del mismo. |
WO2022140516A1 (en) * | 2020-12-22 | 2022-06-30 | Insmed Incorporated | Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease |
CA3207466A1 (en) * | 2021-02-05 | 2022-08-11 | Lingyun Wu | Fused ring derivatives containing 1,4-oxazepane |
AU2022376535A1 (en) * | 2021-10-29 | 2024-05-02 | Insmed Incorporated | Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis |
WO2023134656A1 (zh) * | 2022-01-11 | 2023-07-20 | 上海壹典医药科技开发有限公司 | 一种肽基腈类化合物及其应用 |
WO2023159120A1 (en) * | 2022-02-16 | 2023-08-24 | Insmed Incorporated | Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa |
WO2023160542A1 (zh) * | 2022-02-22 | 2023-08-31 | 四川海思科制药有限公司 | 二肽基肽酶抑制剂化合物的盐及晶型 |
WO2023160541A1 (zh) * | 2022-02-22 | 2023-08-31 | 四川海思科制药有限公司 | 一种含氮杂环化合物的制备方法 |
TW202333739A (zh) * | 2022-02-22 | 2023-09-01 | 大陸商四川海思科製藥有限公司 | 二肽基肽酶1抑制劑多晶型物及其製備方法和用途 |
CN114644562B (zh) * | 2022-04-29 | 2023-08-22 | 常州大学 | 具有红移荧光发射的有机小分子荧光化合物、制备方法及应用 |
WO2023236877A1 (zh) * | 2022-06-07 | 2023-12-14 | 瑞石生物医药有限公司 | 苯并[c]色满化合物的可药用盐、其多晶型及用途 |
TW202404960A (zh) * | 2022-06-07 | 2024-02-01 | 大陸商瑞石生物醫藥有限公司 | 苯并[c]色滿化合物的多晶型及其製備方法和用途 |
WO2024008680A1 (en) | 2022-07-06 | 2024-01-11 | Chiesi Farmaceutici S.P.A. | Azetidine derivatives and use thereof as dipeptidyl peptidase 1 inhibitors |
WO2024081889A1 (en) | 2022-10-14 | 2024-04-18 | Genesis Therapeutics, Inc. | 4h-pyrido[1,2-a]pyrimidin-4-one derivatives for treating cancer |
WO2024088307A1 (zh) * | 2022-10-26 | 2024-05-02 | 上海壹迪生物技术有限公司 | 一种新型肽基腈类化合物及其应用 |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2782151B2 (ja) | 1993-07-16 | 1998-07-30 | 博 吉田 | 衝撃吸収柵用の端ストッパ |
US6297239B1 (en) | 1997-10-08 | 2001-10-02 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
US6462076B2 (en) | 2000-06-14 | 2002-10-08 | Hoffmann-La Roche Inc. | Beta-amino acid nitrile derivatives as cathepsin K inhibitors |
DK1317555T3 (da) | 2000-09-08 | 2008-03-25 | Prozymex As | Dipeptidylpeptidase i krystalstruktur og anvendelser heraf |
EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
PL370766A1 (en) | 2001-12-04 | 2005-05-30 | F.Hoffmann-La Roche Ag | Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors |
US20040253311A1 (en) | 2002-12-18 | 2004-12-16 | Roger Berlin | Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines |
WO2004076434A1 (en) | 2003-02-28 | 2004-09-10 | Aic | Dipeptidyl peptidase inhibitors |
US7893096B2 (en) | 2003-03-28 | 2011-02-22 | Novartis Vaccines And Diagnostics, Inc. | Use of small molecule compounds for immunopotentiation |
ATE399763T1 (de) | 2003-05-30 | 2008-07-15 | Prozymex As | Proteasehemmer |
JP2006527704A (ja) * | 2003-06-18 | 2006-12-07 | プロザイメックス・アクティーゼルスカブ | プロテアーゼ阻害剤 |
PT2206728T (pt) | 2004-04-07 | 2018-04-17 | Rinat Neuroscience Corp | Métodos de tratamento da dor associada ao cancro ósseo através da administração de um anticorpo antagonista do fator de crescimento nervoso |
US20070286854A1 (en) | 2004-04-28 | 2007-12-13 | Bayer Healthcare Ag | Diagnostics And Therapeutics For Diseases Associated With Dipeptidyl-Peptidase 1 (Dpp1) |
US7618981B2 (en) | 2004-05-06 | 2009-11-17 | Cytokinetics, Inc. | Imidazopyridinyl-benzamide anti-cancer agents |
SE0401657D0 (sv) | 2004-06-24 | 2004-06-24 | Astrazeneca Ab | Chemical compounds |
CN1976678B (zh) | 2004-06-29 | 2010-06-02 | 奈康明丹麦有限责任公司 | 水不溶性药快速释放药物组合物的制造方法及通过本方法得到的药物组合物 |
US20090054358A1 (en) | 2004-07-19 | 2009-02-26 | The John Hopkins University | Flt3 inhibitors for immune suppression |
SI3248600T1 (sl) | 2005-02-18 | 2020-09-30 | Abraxis Bioscience, Llc | Kombinacije in načini dajanja terapevtskih sredstev in kombinacijska terapija |
WO2007005668A2 (en) | 2005-06-30 | 2007-01-11 | Amgen Inc. | Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer |
EP2139887A2 (en) | 2007-03-07 | 2010-01-06 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors containing a heterocyclic moiety |
TW200916447A (en) | 2007-08-29 | 2009-04-16 | Methylgene Inc | Sirtuin inhibitors |
US20100282247A1 (en) | 2007-09-25 | 2010-11-11 | Novartis Ag | Treatment of pulmonary disorders with aerosolized medicaments such as vancomycin |
EA201000958A1 (ru) * | 2007-12-12 | 2010-12-30 | Астразенека Аб | Пептидилнитрилы и их применение в качестве ингибиторов дипептидилпептидазы i |
US9315449B2 (en) | 2008-05-15 | 2016-04-19 | Duke University | Substituted pyrazoles as heat shock transcription factor activators |
PE20100252A1 (es) | 2008-06-06 | 2010-04-12 | Boehringer Ingelheim Int | Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina |
MX2011006108A (es) | 2008-12-08 | 2011-11-18 | Vm Pharma Llc | Composiciones de inhibidores de los receptores tirosina quinasa. |
BRPI1016132B8 (pt) | 2009-04-01 | 2021-05-25 | Bial Portela & Ca Sa | composição, formulação farmacêutica, processo de obtenção de uma formulação farmacêutica estável |
CN102574830A (zh) * | 2009-05-07 | 2012-07-11 | 阿斯利康(瑞典)有限公司 | 取代的1-氰基乙基杂环基甲酰胺化合物750 |
WO2010142985A1 (en) * | 2009-06-10 | 2010-12-16 | Astrazeneca Ab | Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761 |
HUE056525T2 (hu) | 2010-04-07 | 2022-02-28 | Vertex Pharma | 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)ciklopropánkarboxamido)-3-metilpiridin-2-il)benzoesav gyógyszerészeti készítményei és azok adagolása |
WO2011154677A1 (en) * | 2010-06-09 | 2011-12-15 | Astrazeneca Ab | Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760 |
IT1404036B1 (it) | 2010-12-17 | 2013-11-08 | Oto Melara Spa | Veicolo armato con struttura migliorata. |
SG192669A1 (en) | 2011-02-11 | 2013-09-30 | Glaxosmithkline Ip Dev Ltd | Cathepsin c inhibitors |
WO2012119941A1 (en) | 2011-03-04 | 2012-09-13 | Prozymex A/S | Peptidyl nitrilcompounds as peptidase inhibitors |
US8999975B2 (en) | 2011-09-19 | 2015-04-07 | Boehringer Ingelheim International Gmbh | Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C |
AU2013224421B2 (en) | 2012-02-21 | 2017-03-02 | Merck Patent Gmbh | 8 - substituted 2 -amino - [1,2,4] triazolo [1, 5 -a] pyrazines as Syk tryrosine kinase inhibitors and GCN2 serin kinase inhibitors |
US9328118B2 (en) | 2012-04-17 | 2016-05-03 | Astellas Pharma Inc. | Nitrogen-containing bicyclic aromatic heterocyclic compound |
WO2014091443A1 (en) | 2012-12-13 | 2014-06-19 | Glaxo Group Limited | Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis |
EP2775304A1 (en) | 2013-03-07 | 2014-09-10 | Universitätsspital Basel | Methods for detecting inflammatory disorder |
WO2014140091A1 (en) | 2013-03-14 | 2014-09-18 | Boehringer Ingelheim International Gmbh | Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c |
WO2014140081A1 (en) | 2013-03-14 | 2014-09-18 | Boehringer Ingelheim International Gmbh | Substituted bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c |
US8871783B2 (en) | 2013-03-14 | 2014-10-28 | Boehringer Ingelheim International Gmbh | Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano-methyl)-amides inhibitors of cathepsin C |
CN108707140B (zh) | 2013-03-14 | 2022-07-22 | 勃林格殷格翰国际有限公司 | 蛋白酶c抑制剂 |
UY35400A (es) | 2013-03-15 | 2014-10-31 | Novartis Ag | Compuestos y composiciones para el tratamiento de enfermedades parasitarias |
WO2014165303A1 (en) | 2013-04-01 | 2014-10-09 | Pulmatrix, Inc. | Tiotropium dry powders |
EA029030B1 (ru) | 2013-09-09 | 2018-01-31 | Прозюмекс А/С | Пептидилнитрильные соединения в качестве ингибиторов дипептидилпептидазы i |
WO2015032942A1 (en) | 2013-09-09 | 2015-03-12 | Prozymex A/S | N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors |
NO2699580T3 (es) | 2014-01-24 | 2018-02-24 | ||
MX2016014921A (es) | 2014-05-15 | 2017-07-28 | Insmed In Incorporated | Metodos para tratar infecciones pulmonares micobacterianas no tuberculosas. |
EP3149192B1 (en) | 2014-05-30 | 2019-01-02 | Versitech Limited | Methods and compositions for use of neutrophil elastase and proteinase 3 as diagnostic biomarkers |
JP6529575B2 (ja) | 2014-08-01 | 2019-06-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換オキセタンおよびそれらのカテプシンcの阻害薬としての使用 |
EA031376B1 (ru) | 2014-09-12 | 2018-12-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Спироциклические ингибиторы катепсина с |
CA2965566A1 (en) | 2014-11-14 | 2016-05-19 | Boehringer Ingelheim International Gmbh | Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (sstr4) agonists |
JP6783426B2 (ja) | 2015-03-05 | 2020-11-11 | ニュープロザイム・セラピューティクス・アンパルトセルスカブNeuprozyme Therapeutics ApS | ジペプチジルペプチダーゼi阻害剤としてのペプチジルニトリル化合物 |
US20180028541A1 (en) | 2016-07-29 | 2018-02-01 | Astrazeneca Ab | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors for treating bronchiectasis |
US20190247400A1 (en) * | 2018-02-07 | 2019-08-15 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating granulomatosis with polyangiitis |
EP3758708A1 (en) | 2018-03-01 | 2021-01-06 | AstraZeneca AB | Pharmaceutical compositions comprising (2s)--{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide |
US20210322438A1 (en) | 2018-07-17 | 2021-10-21 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis |
JP2021530513A (ja) | 2018-07-17 | 2021-11-11 | インスメッド インコーポレイテッド | 炎症性腸疾患を処置するための特定の(2s)−n−[(1s)−1−シアノ−2−フェニルエチル]−1,4−オキサゼパン−2−カルボキサミド |
AU2020289560A1 (en) | 2019-06-05 | 2021-12-23 | Emory University | Peptidomimetics for the treatment of coronavirus and picornavirus infections |
WO2022140516A1 (en) | 2020-12-22 | 2022-06-30 | Insmed Incorporated | Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease |
WO2022232420A1 (en) | 2021-04-29 | 2022-11-03 | Insmed Incorporated | Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cancer |
CA3215375A1 (en) | 2021-04-29 | 2022-11-03 | Insmed Incorporated | Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cystic fibrosis |
-
2012
- 2012-04-15 NO NO12774761A patent/NO2699580T3/no unknown
-
2015
- 2015-01-21 US US14/601,371 patent/US9522894B2/en active Active
- 2015-01-23 AU AU2015208932A patent/AU2015208932C1/en active Active
- 2015-01-23 JP JP2016548068A patent/JP6469711B2/ja active Active
- 2015-01-23 UY UY0001035963A patent/UY35963A/es not_active Application Discontinuation
- 2015-01-23 EP EP20173862.2A patent/EP3744714A1/en active Pending
- 2015-01-23 WO PCT/GB2015/050155 patent/WO2015110826A1/en active Application Filing
- 2015-01-23 MX MX2016009349A patent/MX368840B/es active IP Right Grant
- 2015-01-23 RS RS20180069A patent/RS56919B1/sr unknown
- 2015-01-23 SI SI201531287T patent/SI3323814T1/sl unknown
- 2015-01-23 BR BR112016016224-2A patent/BR112016016224B1/pt active IP Right Grant
- 2015-01-23 EA EA201691375A patent/EA032794B1/ru unknown
- 2015-01-23 SI SI201530170T patent/SI3097086T1/en unknown
- 2015-01-23 SG SG11201606052TA patent/SG11201606052TA/en unknown
- 2015-01-23 CA CA2935625A patent/CA2935625C/en active Active
- 2015-01-23 PL PL17195612T patent/PL3323814T3/pl unknown
- 2015-01-23 ES ES15701577.7T patent/ES2658516T3/es active Active
- 2015-01-23 SG SG10201701056QA patent/SG10201701056QA/en unknown
- 2015-01-23 HU HUE17195612A patent/HUE052421T2/hu unknown
- 2015-01-23 DK DK15701577.7T patent/DK3097086T3/en active
- 2015-01-23 CR CR20160327A patent/CR20160327A/es unknown
- 2015-01-23 EP EP17195612.1A patent/EP3323814B1/en active Active
- 2015-01-23 PL PL15701577T patent/PL3097086T3/pl unknown
- 2015-01-23 NZ NZ722063A patent/NZ722063A/en unknown
- 2015-01-23 LT LTEP15701577.7T patent/LT3097086T/lt unknown
- 2015-01-23 EP EP15701577.7A patent/EP3097086B1/en active Active
- 2015-01-23 PE PE2016001236A patent/PE20161218A1/es unknown
- 2015-01-23 AR ARP150100202A patent/AR099177A1/es active IP Right Grant
- 2015-01-23 PT PT171956121T patent/PT3323814T/pt unknown
- 2015-01-23 CN CN201910716882.4A patent/CN110483492B/zh active Active
- 2015-01-23 RS RS20200858A patent/RS60639B1/sr unknown
- 2015-01-23 DK DK17195612.1T patent/DK3323814T3/da active
- 2015-01-23 LT LTEP17195612.1T patent/LT3323814T/lt unknown
- 2015-01-23 AP AP2016009322A patent/AP2016009322A0/en unknown
- 2015-01-23 PT PT157015777T patent/PT3097086T/pt unknown
- 2015-01-23 ES ES17195612T patent/ES2808060T3/es active Active
- 2015-01-23 CN CN201580005484.1A patent/CN105980367B/zh active Active
- 2015-01-23 MY MYPI2016702657A patent/MY194850A/en unknown
- 2015-01-23 NZ NZ734768A patent/NZ734768A/en unknown
- 2015-01-23 KR KR1020167022665A patent/KR102417684B1/ko active IP Right Grant
- 2015-01-23 HU HUE15701577A patent/HUE038274T2/hu unknown
- 2015-01-23 TW TW104102345A patent/TWI690517B/zh active
-
2016
- 2016-07-05 IL IL246614A patent/IL246614B/en active IP Right Grant
- 2016-07-13 DO DO2016000175A patent/DOP2016000175A/es unknown
- 2016-07-20 PH PH12016501439A patent/PH12016501439B1/en unknown
- 2016-07-25 CL CL2016001889A patent/CL2016001889A1/es unknown
- 2016-08-23 ZA ZA2016/05856A patent/ZA201605856B/en unknown
- 2016-11-08 US US15/346,411 patent/US9815805B2/en active Active
- 2016-12-12 HK HK16114117A patent/HK1225730B/zh unknown
-
2017
- 2017-01-18 AU AU2017200338A patent/AU2017200338B2/en active Active
- 2017-06-11 IL IL252836A patent/IL252836A0/en active IP Right Grant
- 2017-09-19 US US15/708,634 patent/US10287258B2/en active Active
-
2018
- 2018-01-22 HR HRP20180116TT patent/HRP20180116T1/hr unknown
- 2018-01-22 ZA ZA2018/00431A patent/ZA201800431B/en unknown
- 2018-02-05 CY CY20181100132T patent/CY1120049T1/el unknown
- 2018-04-30 AU AU2018202956A patent/AU2018202956B2/en active Active
- 2018-11-22 HK HK18114946.6A patent/HK1255870A1/zh unknown
-
2019
- 2019-01-16 JP JP2019005300A patent/JP6804570B2/ja active Active
- 2019-03-19 US US16/358,091 patent/US10669245B2/en active Active
- 2019-03-25 IL IL265611A patent/IL265611A/en unknown
- 2019-04-17 AU AU2019202675A patent/AU2019202675B2/en active Active
-
2020
- 2020-04-22 US US16/855,522 patent/US11117874B2/en active Active
- 2020-07-23 CY CY20201100674T patent/CY1123391T1/el unknown
- 2020-07-23 HR HRP20201147TT patent/HRP20201147T1/hr unknown
- 2020-12-02 JP JP2020200413A patent/JP7157791B2/ja active Active
-
2021
- 2021-02-08 US US17/170,641 patent/US11667615B2/en active Active
-
2022
- 2022-04-04 JP JP2022062548A patent/JP7336563B2/ja active Active
- 2022-09-09 US US17/942,111 patent/US11773069B2/en active Active
- 2022-09-09 US US17/942,106 patent/US11655221B2/en active Active
- 2022-09-10 US US17/942,112 patent/US11673871B2/en active Active
- 2022-09-10 US US17/942,121 patent/US11655223B2/en active Active
- 2022-09-10 US US17/942,123 patent/US11814359B2/en active Active
- 2022-09-10 US US17/942,120 patent/US11655222B2/en active Active
- 2022-09-10 US US17/942,122 patent/US11655224B2/en active Active
- 2022-09-15 US US17/946,024 patent/US11680049B2/en active Active
- 2022-09-16 US US17/946,112 patent/US11673872B2/en active Active
-
2023
- 2023-04-13 US US18/300,350 patent/US20230250071A1/en not_active Abandoned
- 2023-08-21 JP JP2023133935A patent/JP2023156479A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20161218A1 (es) | (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
DOP2019000010A (es) | Compuesto (r)-n-(5-cloro-1-(3,3-difluoro-1-(oxetan-3-il)piperidin-4-il)-1h-pirazol-4-il)-4-etoxi-7h-pirrolo[2,3-d]pirimidin-2-amina o sal farmacéuticamente aceptable del mismo | |
EA201691803A1 (ru) | Ингибиторы калликреина плазмы человека | |
UY35243A (es) | Inhibidores de fosfatidilinositol 3-cinasa | |
PE20161225A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
TN2014000033A1 (fr) | Indazoles | |
PE20141824A1 (es) | Compuestos terapeuticamente activos y sus metodos de uso | |
UY35242A (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
PE20142305A1 (es) | Compuestos de n-ariltriazol como antagonistas de lpar | |
EA201491329A1 (ru) | 4,4-дизамещенные 1,4-дигидропиримидины и их применение в качестве лекарственных препаратов для лечения гепатита b | |
EA201790088A1 (ru) | Ингибиторы syk | |
PE20160194A1 (es) | Composiciones y metodos para tratar anemia | |
CU20140072A7 (es) | Derivados de dihidro-oxazina y dihidro-pirido-oxazina | |
EA201391720A1 (ru) | Замещенные диоксопиперидинилфталимидные производные | |
PE20161432A1 (es) | Compuestos y composiciones para inducir condrogenesis | |
EA201391486A1 (ru) | Способы и композиции для лечения болезни паркинсона | |
PE20151666A1 (es) | Derivados sustituidos del acido bisfenil butanoico fosfonico como inhibidores de la nep | |
EA201390428A1 (ru) | Композиции и способы лечения легочной гипертензии | |
EA201391337A1 (ru) | Ингибиторы hsp90 | |
GEP20186880B (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
EA201391334A1 (ru) | Ингибиторы hsp90 | |
AR084144A1 (es) | Compuestos y metodos para restaurar la piel | |
PE20170914A1 (es) | 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3,2-d]pirimidin-4-onas como inhibidores de mieloperoxidasa | |
PE20142337A1 (es) | Sales de 5-[(1r)-2-({2-[4-(2,2-difluoro-2-feniletoxi)fenil]etil}amino)-1-hidroxietil]-8-hidroxiquinolin-2(1h)-ona | |
PE20190972A1 (es) | Combinacion de agonistas de fxr |